| WARF: P06394US |  |
| Methods for Reducing Body Fat Using Vitamin D Compounds |
| INVENTORS | • | Hector DeLuca, Lori Plum, Hau Zhe Ke, Thomas Brown |
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a method of using a vitamin D analog to reduce body fat.
OVERVIEW
In the United States, more than 60 percent of the population is considered overweight or obese. Current treatments, including pharmacological and/or surgical intervention, diet modification and appetite suppression, are not adequate to prevent this growing epidemic.
THE INVENTION
UW-Madison researchers have developed a method of using a vitamin D analog to treat obesity. When administered to an overweight person or other animal, a 2-alkylidene derivative of vitamin D3 effectively maintains or increases lean body mass while reducing overall body weight and fat. It can alleviate many symptoms of menopause by controlling weight gain and the accompanying cardiovascular risk, while having a beneficial effect on bone metabolism and osteogenesis.
APPLICATIONS
- Reducing body
- Treating menopausal symptoms
KEY BENEFITS
- Decreases body fat and weight without reducing lean body mass
- Inhibits an increase in body fat in people or animals at-risk
- Increases bone mass and osteogenesis, making it a useful treatment for symptoms of menopause
- Does not require dieting or surgical intervention
STAGE OF DEVELOPMENT
When experimental animals, including ovariectomized rats, were given a 2-alkylidene-19-nor vitamin D analog, they experienced significant fat loss without loss of muscle mass.
ADDITIONAL INFORMATION
For More Information About the Inventors
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Vitamin D
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
WARF: A Leader in Technology Transfer Since 1925
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
